UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 80

Sortiert nach

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Link zum Volltext

Verfügbarkeit prüfen

mTOR Inhibition for Cancer Therapy: Past, Present and Future

1st ed. 2016, 2015

Link zum Volltext

Verfügbarkeit prüfen

Vascular endothelial growth factor receptor‐1 in human cancer

Cancer, 2010-02, Vol.116 (S4), p.1027-1032

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic study of Al-850, A novel microparticle hydrophobic drug delivery system for paclitaxel

Clinical cancer research, 2007-06, Vol.13 (11), p.3293-3301

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus

Cancer research (Chicago, Ill.), 2021-11, Vol.81 (22_Supplement), p.PO-018-PO-018

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2589-2589

2017

Link zum Volltext

Verfügbarkeit prüfen

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Blood, 2014-12, Vol.124 (21), p.4500-4500

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4507: SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4507-4507

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily × 5 Schedule in Patients with Solid Malignancies

Clinical cancer research, 2002-01, Vol.8 (1), p.75

2002

Link zum Volltext

Verfügbarkeit prüfen

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

Investigational new drugs, 2007-08, Vol.25 (4), p.357-357

2007

Link zum Volltext

Verfügbarkeit prüfen

Drug therapy : paclitaxel (Taxol)

The New England journal of medicine, 1995-04, Vol.332 (15), p.1004-1014

1995

Link zum Volltext

Verfügbarkeit prüfen

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Blood, 2013-11, Vol.122 (21), p.4104-4104

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT146-CT146

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-06-07: StemScreen®, an innovative platform technology for the identification of novel cancer stem cell-directed compounds

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P2-P2-06-07

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.716-716

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-133-LB-133

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3095-3095

2018

Link zum Volltext

Verfügbarkeit prüfen

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

Blood, 2014-12, Vol.124 (21), p.5663-5663

2014

Link zum Volltext

Verfügbarkeit prüfen

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma

Blood, 2012-11, Vol.120 (21), p.2768-2768

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B001-B001

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT235-CT235

2023

Link zum Volltext

Verfügbarkeit prüfen

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Blood, 2015-12, Vol.126 (23), p.4433-4433

2015

Link zum Volltext

Verfügbarkeit prüfen

The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases

Emerging drugs, 2000-07, Vol.5 (2), p.161-199

2000

Link zum Volltext

Verfügbarkeit prüfen

Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8582-8582

2013

Link zum Volltext

Verfügbarkeit prüfen

Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8599-8599

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 80

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(80)

Publikationsform

Sprache

Englisch
(80)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

mTOR Inhibition for Cancer Therapy: Past, Present and Future

Vascular endothelial growth factor receptor‐1 in human cancer

Phase I and pharmacokinetic study of Al-850, A novel microparticle hydrophobic drug delivery system for paclitaxel

Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma

Abstract 4507: SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily × 5 Schedule in Patients with Solid Malignancies

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes

Drug therapy : paclitaxel (Taxol)

SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia

Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts

Abstract P2-06-07: StemScreen®, an innovative platform technology for the identification of novel cancer stem cell-directed compounds

A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report

Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases

Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance

Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease

Aktive Filter

Suchergebnisse filtern